Comparative Pharmacology
Head-to-head clinical analysis: PROSOL 20 SULFITE FREE IN PLASTIC CONTAINER versus TRAVASOL 2 75 SULFITE FREE W ELECTROLYTES IN DEXTROSE 15 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROSOL 20 SULFITE FREE IN PLASTIC CONTAINER versus TRAVASOL 2 75 SULFITE FREE W ELECTROLYTES IN DEXTROSE 15 IN PLASTIC CONTAINER.
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER vs TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propofol is a short-acting intravenous anesthetic agent that potentiates GABA-A receptor activity, resulting in rapid loss of consciousness through inhibition of neuronal firing in the central nervous system.
Travasol 2.75% with electrolytes in dextrose 15% is a parenteral nutrition formulation. It provides amino acids for protein synthesis, dextrose for caloric energy, and electrolytes for maintaining homeostasis. Dextrose stimulates insulin release and provides glucose for cellular metabolism. Amino acids are utilized for tissue repair and nitrogen balance. Electrolytes maintain acid-base balance, neuromuscular function, and enzymatic processes.
Intravenous infusion: 20 mL/kg (4 g/kg) as a 20% solution administered over 2-4 hours. May repeat up to 100 mL/kg/day if needed.
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER is a total parenteral nutrition (TPN) solution. Adult dosing is based on caloric and protein needs: typically 1-2 L/day intravenously, providing 15% dextrose (150 g/L) and 2.75% amino acids (27.5 g/L). Infusion rate initially 1.5-2 mL/min, adjusted to meet metabolic requirements.
None Documented
None Documented
Terminal elimination half-life is approximately 1–2 hours in healthy individuals; may be prolonged in renal impairment due to accumulation of metabolites.
Not applicable (mixture of nutrients with endogenous clearance). Glucose: ~1-2 h; amino acids: ~0.5-2 h; electrolytes: vary.
Renal excretion of unchanged drug is minimal (<5%). The majority is metabolized via the tricarboxylic acid cycle to CO2 and water. Biliary/fecal elimination is negligible.
Renal: 100% (as glucose, amino acids, and electrolytes). Biliary/fecal: negligible.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution